Summary & Overview
HCPCS J9120: Injection, Dactinomycin 0.5 mg
HCPCS Level II code J9120 denotes the injectable chemotherapeutic agent dactinomycin in 0.5 mg units. As a drug-specific HCPCS code used in outpatient and infusion settings, it is central to billing for cytotoxic therapy administration and inventory tracking. Nationally, accurate use of this code affects provider reimbursement, drug utilization reporting, and oncology supply management.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns, billing benchmarks, and common claim considerations for J9120 across commercial and government payers.
Readers will learn: how J9120 is described clinically and operationally; typical sites of service for administration; common payer coverage landscape; and the types of benchmarks and policy topics that influence billing for injectable chemotherapy agents. Where specific input data are missing, the publication flags those gaps as "Data not available in the input." The content is designed to inform coding staff, revenue cycle managers, and policy analysts about the role of HCPCS Level II code J9120 in oncology billing workflows and payer interactions.
Billing Code Overview
HCPCS Level II code J9120 represents an injection of dactinomycin, 0.5 mg. This itemized drug service describes a chemotherapeutic agent supplied for parenteral administration. The service type is injectable chemotherapy administration. The typical site of service is hospital outpatient departments, oncology clinics, and infusion centers where intravenous or intramuscular chemotherapy agents are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology patient requiring systemic chemotherapy for a malignancy such as Wilms tumor, rhabdomyosarcoma, gestational trophoblastic disease, or certain soft-tissue sarcomas. The medication J9120 (dactinomycin 0.5 mg) is administered as an intravenous injection or short infusion in an outpatient oncology clinic, hospital outpatient infusion center, or inpatient oncology ward. The usual workflow: the oncologist documents the indication, chemotherapy regimen, dose, and schedule in the medical record; the oncology pharmacist compounds the dose based on body surface area or protocol; a registered nurse verifies patient identity, pre-meds, and vascular access; the medication is administered with vital sign monitoring and toxicity assessment; administration details (date, time, dose, lot number, route, and any immediate reactions) are documented in the medication administration record; and the facility bills HCPCS code J9120 with appropriate modifier(s) reflecting the service circumstance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — default billing | Use when no additional modifier applies to the service. |